Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and
exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR)
Cardiac Amyloidosis.